Rapid Uptake of Skyrizi Protects the AbbVie Portfolio in Plaque Psoriasis as Humira Share Continues to Dwindle in the First-Line Setting
Momentum builds for the newest market entrant as use in biologic-naïve psoriasis patients surpasses all alternative mechanism of action biologics within its first year of launching, according to patient level data collected by Spherix Global Insights EXTON, Pa., June 9, 2020 /PRNewswire/ — The 2020 audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule New Starts […]
Specialty Physicians Report Signs of Rebound from COVID-19, but Are Pessimistic About Reopening Without a Resurgence
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely depressed and physicians are worried about patients with non-COVID conditions being able to access care EXTON, Pa., May 27, 2020 / PRNewswire / – Since the end of March, Spherix Global Insights has been tracking […]
Specialty Physicians Predict More Pain Ahead in the Battle Against COVID-19
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to the latest update from Spherix Global Insights EXTON, Pa., April 9, 2020 / PRNewswire / – Special Report: Multi-Specialty Impact of COVID-19 is an independent project being run by Spherix to assess the impact of […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
With a plethora of agents in development, manufacturers who already have one leg in the dermatology biologic/small molecule space, such as AbbVie, Amgen, Eli Lilly, Janssen, and Novartis could have a competitive edge over more novel developers. EXTON, Pa., March 17, 2020 /PRNewswire/ — The past decade has ushered in an array of new treatment […]
Positive Growth of Eli Lilly’s Taltz and Stabilization of Novartis’ Cosentyx in Psoriasis May be an Indicator for Future Psoriatic Arthritis Market Shift
Cosentyx’s first-to-market status in psoriasis, psoriatic arthritis, and ankylosing spondylitis has historically provided the brand with a competitive edge over in-class rival, Taltz, though recent studies conducted by Spherix Global Insights indicate changes are afoot EXTON, Pa., October 10, 2019 /PRNewswire/ — Novartis’ Cosentyx was first approved by the FDA for the treatment of psoriasis in […]
Recent Studies Reveal Flare Rates Among Dupixent-Treated Patients with Moderate-to-Severe Atopic Dermatitis
Spherix Global Insights provides an independent perspective on the atopic dermatitis market. EXTON, Pa., September 5, 2019 /PRNewswire/ — Atopic dermatitis (AD), commonly referred to as eczema, affects millions of children and adults across the globe. In 2017, Regeneron/Sanofi’s Dupixent, an IL-4/13 blocker, became the first approved biologic to treat adults with more severe forms of […]
Robust Use of Janssen’s Tremfya and Positive Early Launch Metrics for AbbVie’s Skyrizi May Threaten Growth of IL-17 Inhibitors in US Psoriasis Market, According to Spherix Global Insights
The US psoriasis landscape has come a long way since the first introduction of an alternate mechanism of action agent in a previously TNF-dominant market; IL-23 inhibitors are now in the spotlight EXTON, Pa., July 25, 2019 /PRNewswire/ — Spherix began tracking the US psoriasis market through its RealTime Dynamix™: Psoriasis (US) service in early […]
US Dermatologists Report a Sizeable Portion of Their Atopic Dermatitis Patients Currently Treated with Sanofi/Regeneron’s Dupixent Would be Switched to Another Targeted Therapy if Available
According to a recent study conducted by Spherix Global Insights, Dupixent continues to be well-received amongst US dermatologists, though overall use will likely take a hit once new advance systemic treatments become available. Download Report Overview EXTON, Pa., May 15, 2019 /PRNewswire/ —In Spherix’s second quarter update of RealTime Dynamix™: Atopic Dermatitis (US), Sanofi/Regeneron’s Dupixent […]
In Psoriasis, Use of the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, are Neck and Neck, but the Former Still Holds a Significant First-to-Market Edge Amongst Rheumatologists for the Treatment of Psoriatic Arthritis, According to Data Recently Collected by Spherix Global Insights
After several years on the market, the majority of US dermatologists report that Cosentyx has lost its advantage over Taltz as the first IL-17 inhibitor on the market; with increased penetration of Taltz for the treatment of psoriatic arthritis, will rheumatologists follow suit? Download Report Overview EXTON, Pa., April 17, 2019 /PRNewswire/ — Spherix Global Insights […]
